Last reviewed · How we verify

EM-100 — Competitive Intelligence Brief

EM-100 (EM-100) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Wnt/β-catenin pathway inhibitor. Area: Ophthalmology.

phase 3 Wnt/β-catenin pathway inhibitor Wnt/β-catenin signaling pathway Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

EM-100 (EM-100) — Bausch & Lomb Incorporated. EM-100 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EM-100 TARGET EM-100 Bausch & Lomb Incorporated phase 3 Wnt/β-catenin pathway inhibitor Wnt/β-catenin signaling pathway
ISV-403 ISV-403 Bausch & Lomb Incorporated phase 3 Wnt/β-catenin pathway inhibitor Wnt/β-catenin signaling pathway
BBI608 BBI608 NCIC Clinical Trials Group phase 3 Wnt/β-catenin pathway inhibitor β-catenin / Wnt signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Wnt/β-catenin pathway inhibitor class)

  1. Bausch & Lomb Incorporated · 2 drugs in this class
  2. NCIC Clinical Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EM-100 — Competitive Intelligence Brief. https://druglandscape.com/ci/em-100. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: